Nurix Therapeutics (NRIX) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The PRIME, or priority medicines, designation follows "encouraging" safety and efficacy data from an ongoing phase 1 trial, the company said.
To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data, the firm said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。